The efficacy of talymus ophthalmic suspension in the treatment of ocular autoimmune disease

The efficacy of talymus ophthalmic suspension in the treatment of ocular autoimmune disease - The efficacy of talymus ophthalmic suspension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034460

Enrollment

Registered

2018-10-15

Start date

2015-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scleritis, keratoconjunctivitis, corneal transplantation

Interventions

Talymus Ophthalmic Suspension 0.1%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received a full explanation on the objectives and methods of the study, expected effects and adverse drug reactions, respect for the privacy, recompense and compensation, and who themselves or their legal representatives voluntarily provided consent for study participation.

Exclusion criteria

Exclusion criteria: Subjects who doctors consider ineligible for enrollment.

Design outcomes

Primary

Measure	Time frame
itching	—

Secondary

Measure	Time frame
visual acuity, hyperemia, ocular pain, corneal epithelial disorders, corneal edema, chemosis, eyelid swelling, conjunctival papillae, conjunctival follicle, intraocular pressure (IOP), necessity of steroid and/or anti-allergic drug therapy, corneal endothelial cell density	—

Countries

Japan

Contacts

Public ContactHiroshi Fujishima

Tsurumi University Faculty of Dentistry

fujishima117@gmail.com0455808599

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026